From Wikipedia, the free encyclopedia
Ticagrelor (Brilinta) is often listed with thienopyridine inhibitors and has similar indications for use but is not a thienopyridine. It is a cyclo-pentyltriazolo-pyrimidine that reversibly inhibits the P2Y12 receptor.
- Alexopoulos, Dimitrios (2014). "P2Y12 Receptor Inhibitors in Acute Coronary Syndromes: From the Research Laboratory to the Clinic and Vice Versa". Cardiology. 127 (4): 211–219. doi:10.1159/000357399.
- Depta, Jeremiah P.; Bhatt, Deepak L. (2008-01-01). "Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance". American Journal of Cardiovascular Drugs: Drugs, Devices, and Other Interventions. 8 (2): 91–112. ISSN 1175-3277. PMID 18422393.
- Angiolillo DJ, Bates ER, Bass TA (August 2008). "Clinical profile of prasugrel, a novel thienopyridine". Am. Heart J. 156 (2 Suppl): S16–22. doi:10.1016/j.ahj.2008.06.005. PMID 18657682.
|This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.|